GrantPostedDiscretionary

Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required)

National Institutes of Health
PAR-23-158
Application Deadline
May 7, 2026
54 days left
Days Remaining
54
Until deadline
Award Ceiling
Total Program Funding

Grant Opportunity Analysis

The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for exploratory clinical neuroscience research on substance use disorders (SUD) through the R61/R33 phased grant mechanism. This initiative aims to enhance understanding of the neurobiological mechanisms underlying SUD, encouraging innovative studies that explore fundamental brain functions and behaviors related to substance use. The program supports clinical research that integrates both basic research and clinical trials, with funding available for up to five years—two years for the R61 phase and three years for the R33 phase, contingent upon achieving defined milestones. Interested applicants from diverse institutions, including higher education and non-profit organizations, are encouraged to submit proposals by May 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-158.html.

Eligible Applicants

Others
Additional Eligibility Information

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Grant Documents

2 Files
PAR-23-158-Full-Announcement.html
HTML0 KB8/24/2024
AI Summary
No AI summary available for this file.
PAR-23-158.html
HTML135 KB8/24/2024
AI Summary
The Department of Health and Human Services, through the National Institutes of Health (NIH), issued a Notice of Funding Opportunity (NOFO) to support exploratory clinical neuroscience research on substance use disorders (SUD) via an R61/R33 phased grant mechanism. The initiative aims to enhance understanding of the neurobiological mechanisms underlying SUD, enabling innovative studies that explore fundamental circuitry and behaviors pertinent to substance use. The program prioritizes clinical research that falls within the definitions of both basic research and clinical trials, pushing for experimental studies with a focus on the underlying mechanisms of SUD. Key components include a phased funding approach, with the potential for up to five years of support—two for the R61 phase and three for the R33 phase, based on the successful achievement of defined milestones. The NOFO encourages applicants from diverse institutions, including higher education and non-profit organizations, to propose novel studies that probe individual differences in neural circuitry, cognitive processes, and interactions with other psychiatric disorders. Applications must adhere to specific guidelines regarding milestones, data management, and submission processes. The overarching aim is to drive scientific breakthroughs in understanding and combating substance use disorders, aligning with current public health priorities amidst rising drug use challenges.

Related Grant Opportunities

Project Timeline

postedOriginal Opportunity PostedApr 10, 2023
deadlineApplication DeadlineMay 7, 2026
expiryArchive DateJun 12, 2026

Funding Details

No cost sharing required

Agency & Classification

Agency
National Institutes of Health(HHS-NIH11)
Funding Category
Health
Funding Instrument
Grant

Grantor Contact

CFDA Numbers

93.279

Official Sources